RSV Observational Study 2
Analysis of the Immune Response to Respiratory Syncytial Virus (RSV) Exposure in a Paediatric Population
Respiratory Syncytial Virus (RSV) is a virus that causes chest infections. It is the single most important cause of severe respiratory illness in infants and young children, and severe RSV infection early in life is associated with an increased risk of later developing asthma. RSV also causes severe disease in elderly and immune-compromised adults, and the amount of RSV disease in the elderly is similar to that from seasonal flu. The virus is transmitted in the secretions of the upper respiratory tract of infected individuals and by contact with contaminated surfaces (such as toys). Hospital outbreaks, especially on paediatric and neonatal wards, are not uncommon.
Infection by RSV does not develop a natural long-lasting protection against re-infection (like, for example, measles does). In the USA nearly all children by 24 months of age have been infected at least once with RSV, and about half will have experienced two infections. There is no effective anti-viral drug to treat an infection and the only way of managing cases of severe infection is through supporting organs, such as the lungs, to withstand and recover from the illness.
There remains a real need to develop an effective vaccine to prevent severe infections caused by RSV. A better understanding of the way the immune system responds to RSV in children would aid the development of such a vaccine.
The purpose of this study is to increase our understanding of how the immune system responds to RSV. Only limited data is available on some important components of the immune response and this study is designed to measure these in more detail. This is done using a single blood sample.
A total of 35 children are anticipated to be recruited to this study, at ages when we expect to see differences in the immune response to RSV;
- 5 infants aged between 2 and 4 months (Group 1), who have not yet been exposed to RSV
- 20 infants aged between 6 and 12 months (Group 2), who will have had exposure to one single RSV season in the winter of 2011/12
- 10 children aged between 3 and 6 years (Group 3), who have been exposed to RSV over several winter seasons
調査の概要
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Oxford、イギリス、OX3 9DU
- Oxford University Hopsitals NHS Trust
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Parent or guardian is willing and able to give informed consent for participation in the study
- Age suitable for Group 1, 2 or 3 as defined in above (Section 6.2)
- Delivery at 36 weeks gestation or later
- Having a blood sample for clinical reasons
Exclusion Criteria:
- Parent or guardian unable or unwilling to give informed consent for participation in the study
- Any impaired function of the immune system, by medication or pathological process, which could augment or impair the immune response to RSV
- Concurrent acute or chronic infection
- Any chronic illness which, in the opinion of the Investigator, may lead to incorrect or inaccurate immunology data
- History of immunoprophylaxis with Palivizumab
- Delivery prior to 36 weeks gestation
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
2-4 months
Infants aged between 2 and 4 months (Group 1), who have not yet been exposed to RSV
|
An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
|
|
6 - 12 months
Infants aged between 6 and 12 months (Group 2), who will have had exposure to one single RSV season in the winter of 2011/12
|
An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
|
|
3 - 6 years
Children aged between 3 and 6 years (Group 3), who have been exposed to RSV over several winter seasons
|
An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To assess the induction of RSV-specific immune responses in blood following natural exposure
時間枠：one year
|
The following assays characterise the primary objective:
|
one year
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Andrew J Pollard、University of Oxford
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2013/01
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。